MedImmune Sr. Director, Partnering & Strategy filling role previously held by Emergent BioSolutions CEO, Daniel J. Abdun-Nabi
BioHealth Innovation, Inc. (BHI) announced that its Board of Directors has unanimously approved the appointment of MedImmune Sr. Director, Partnering & Strategy, Jarrod Borkat as new Vice Chairman. MedImmune, the global biologics research and development arm of AstraZeneca, is a Founding Partner of BHI and continues to be a leader in building the BioHealth Capital Region. BHI would like to thank Emergent BioSolutions CEO, Daniel J. Abdun-Nabi, for his service as Vice Chairman. He will remain as a member of the Board of Directors. Mr. Abdun-Nabi also previously served as chairman of the Maryland Life Sciences Advisory Board (LSAB) and currently serves on Maryland Governor Larry Hogan’s Excel Board.
Company’s announcement latest in recent trend of significant investment in Montgomery County biohealth companies.
BeneVir Biopharm, Inc. (BeneVir), a privately-held Montgomery County biotech company, has entered into an agreement under which it will be acquired by Janssen Biotech, Inc., a Johnson & Johnson company for up to $1.04 billion. Under the terms of the agreement, Janssen will make an upfront cash payment of $140 million at closing of the transaction, plus additional contingent payments of up to $900 million based on achievement of certain predetermined milestones. BeneVir was a client of BioHealth Innovation (BHI) from 2013 until its Series A investment in 2014.
Welcome to the 2018 BioHealth Capital Region Forum: State of the BioHealth Capital Region’s EcoSystem
Presented by: Rich Bendis, President & CEO, BioHealth Innovation Inc.
– Winner to be announced during 2018 BioHealth Capital Region Forum –
Five companies have been selected to present to a panel of investor judges and an audience of industry leaders during the 2018 BioHealth Capital Region Forum, April 23-24, at the MedImmune campus in Gaithersburg, Maryland. Founded by BioHealth Innovation, Inc. (BHI) and MedImmune in 2016, the annual Crab Trap Competition highlights companies from throughout the region in varied stages of business development and industry sectors. Open to applicants from Maryland, DC and Virginia, previous winners are Johns Hopkins University spinouts: LifeSprout (2017) developing the next-generation of synthetic soft tissue substitutes for aesthetic and reconstructive medicine, and Sonavex (2016), developer of a pipeline of novel ultrasound solutions to visualize and quantify critical clinical data for improved outcomes and reduced costs in new surgical applications. The 3rd Annual Crab Trap Competition is sponsored by Wilson Sonsini Goodrich & Rosati. The grand prize includes $10,000, incubation space in either Montgomery County, MD or Prince William County, VA, and business mentoring.
May 1-2, 2018, Washington, D.C.
The event brings together a diverse audience of Fortune 500 corporations, Startup Development Officers (SDOs), university licensing and tech transfer officers, startup creation program managers, university researchers, faculty, federal labs, entrepreneurs, VCs, angel investors, policy leaders, and federal government agencies. The event provides an opportunity for the participants to align university IP and startups with Fortune 500 investor and corporate needs through NCET2’s Startup Development Program that creates startups for Fortune 500 corporations from university and federal lab research.
BioHealth Innovation, Inc. (BHI) has received the International Business Innovation Association (InBIA)’s January 2018 IMPACT Award in Biotech/Cleantech for the management of four spaces for early stage companies: the Germantown Innovation Center, the Rockville Innovation Center, LaunchLabs, and the BHI International Innovation Center. The award is based on a variety of metrics including affiliations and partnerships, application and graduation, facilities, mission and goals. This recognition also enables this innovation activity to be considered with other leading entrepreneurial centers across the country as a finalist for the InBIA’s annual Incubator of the Year Awards.
MCEDC talks with Rich Bendis, President and CEO of BioHealth Innovation, about how his organization fuels the science industry in Montgomery County, Maryland.
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a contract by the Department of National Defence (DND) valued at approximately $8 million to deliver Anthrasil® (Anthrax Immune Globulin Intravenous [human]) to the Canadian government. This contract award follows the recent approval of Anthrasil by Health Canada under the Extraordinary Use New Drug (EUND) Regulations, which provide a regulatory pathway for products for which collecting clinical information for its intended use in humans is logistically or ethically not possible. Anthrasil is indicated for the treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs.